Shots:
- GSK has reported P-III (B-Well 1 & B-Well 2) trial results assessing bepirovirsen vs PBO in over 1,800 pts from 29 countries for the treatment of chronic hepatitis B (CHB)
- Both trials met the 1EP, with bepirovirsen delivering a statistically significant, clinically meaningful functional cure & showing superior cure rates vs SoC; Results were significant across all EPs, incl. robust effects in pts with baseline HBsAg ≤1,000 IU/mL
- Full results will be presented at an upcoming scientific congress, published in a peer-reviewed journal, & used to support global regulatory submissions, with filings planned to begin from Q1’26
Ref: GSK | Image: GSK | Press Release
Related News: GSK Reports the MHLW Approval of Exdensur (Depemokimab) for Severe Asthma and CRSwNP
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
